| 日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
| 2024/05/17 | 08 : 36 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/05/09 | 20 : 12 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/05/09 | 20 : 05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/05/09 | 20 : 00 | Business Wire | Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/05/08 | 22 : 00 | Business Wire | Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/05/02 | 22 : 00 | Business Wire | Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/04/10 | 22 : 00 | Business Wire | Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/04/09 | 18 : 45 | PR Newswire (US) | The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/04/08 | 22 : 00 | Business Wire | Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024 | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/04/05 | 18 : 45 | PR Newswire (US) | Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLX | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/04/04 | 20 : 00 | Business Wire | Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/04/02 | 18 : 45 | PR Newswire (US) | The Gross Law Firm Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/29 | 18 : 45 | PR Newswire (US) | The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/26 | 18 : 45 | PR Newswire (US) | Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLX | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/25 | 21 : 00 | PR Newswire (US) | INVESTOR ALERT: AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) INVESTORS WITH LOSSES OF MORE THAN $100,000 ENCOURAGED TO SEEK APPOINTMENT AS LEAD PLAINTIFF - April 9, 2024 DEADLINE | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/22 | 18 : 45 | PR Newswire (US) | The Gross Law Firm Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/19 | 18 : 45 | PR Newswire (US) | Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLX | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/14 | 22 : 00 | Business Wire | Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/14 | 18 : 50 | PR Newswire (US) | The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 9, 2024 in Amylyx Lawsuit - AMLX | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/11 | 21 : 44 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/11 | 18 : 50 | PR Newswire (US) | Amylyx Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/08 | 21 : 10 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/08 | 21 : 00 | Business Wire | Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/08 | 06 : 05 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/08 | 06 : 05 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/08 | 06 : 05 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/03/07 | 19 : 45 | PR Newswire (US) | Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLX | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/02/29 | 08 : 22 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/02/29 | 08 : 20 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
| 2024/02/29 | 08 : 13 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |